CalciMedica, Inc. (CALC) entered into a securities purchase agreement on June 23, 2026, for a private placement expected to raise approximately $15.0 million in upfront gross proceeds. The financing, involving new and existing institutional investors, is intended to fund the company's focused pulmonary hypertension (PH) strategy and extend its operational runway into the second half of 2027. The agreement also includes warrants that could provide up to an additional $34 million.
Key Details
- Financing Terms: The company will sell 18,673,429 units at a purchase price of approximately $0.8033 per unit, raising gross proceeds of $15.0 million. The closing is expected on or about June 25, 2026.
- Offering Structure: Each unit consists of one share of common stock (or a pre-funded warrant) and rights to receive one Series A warrant and one Series B warrant upon shareholder approval. Full cash exercise of the warrants could generate up to an additional $34 million in gross proceeds.
- Use of Proceeds & Strategy: Net proceeds will advance a Phase 1b proof-of-concept study for Auxora™ in pulmonary arterial hypertension (PAH), with data anticipated in mid-2027, and support development of the company's oral drug candidate, CM5480.
- Insider Participation: Company executives, board members, and affiliated institutional investors are participating in the private placement for an aggregate of 6,908,996 units.